Clinical Trial Search

Primary: Percentage of Participants Who Achieved a Clinical Response by Total Mayo Score at Day 57 — 63.6; 54.5; 54.5 Percentage of participants — p=1.0000

Primary: Change From Baseline in Average Pain Intensity as Measured by the Numeric Rating Scale (NRS) — -0.95; -1.18 score on a scale

Primary: Change in Free-water Accumulation in the Substantia Nigra — 0.0009; 0.0041 arbitrary units (A.U.s)

Primary: Percentage of Participants Achieving Eczema Area and Severity Index-75 (EASI-75) Response at Week 16 — 13.8; 24.1; 34.5 percentage of participants

Primary: Objective Response Rate (ORR) — 81 percentage of patients

Primary: Efficacy - Primary Endpoint During the Blinded Period — 50.0; 40.0; 60.0; 26.7 Percentage of participants — p== 0.2635

Primary: Change From Baseline in Modified Motor Score (mMS) (Sum of Score of Items 4-10 and 13-15 of the UHDRS Motor Assessments) at Week 12 — -1.40; -1.30; -2.49; -2.32 units on…

Primary: Quantitative Assessment - Bile Duct-to-liver Fluorescence Intensity Ratio — 2.7; 0.7 ratio

Primary: Changes in Gut Microbial Translocation (iFABP) — 145.76; 125.36; 151.5; 111.73 pg/mL

Primary: Improvement of Symptoms and Pain — 9 Participants

Primary: Phase 1: Maximum Tolerated Dose (MTD) of Lenvatinib in Combination With Everolimus — 11 milligram per square meter (mg/m^2)

Primary: Safety and Tolerability of VE800 in Combination With Nivolumab: Number of Participants With Adverse Events — 16; 19; 12; 47 participants

Primary: Relative Change From Baseline to Week 36 in the Percentage of Liver Fat Content (LFC) (Assessed by Magnetic Resonance Imaging - Proton Density Fat Fraction [MRI-PDFF])…

Primary: Safety as Assessed by Number of Adverse Events — 4; 5 Adverse Events

Primary: Change From Baseline at Week 8 in the Visual Analog Scale (VAS) for Pain for the Foot — -41.6; -39.3 score on a scale